Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06018272

Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany

Background: Borderline Personality Disorder (BPD) is a serious mental disorder. Mentalization-based treatment (MBT) is one evidence-based treatment for individuals with BPD. Specifically, MBT has been highlighted for its effectiveness in reduction of suicidal and non-suicidal self-injury (NSSI). Yet, randomized-controlled trials (RCT) on MBT in outpatient settings compared with bona fide treatment (BFT) are still scarce and none has been conducted in Germany. The primary objective of this RCT is to investigate whether outpatient MBT is more effective in the reduction of crisis events (incidences of NSSI and suicide attempts) compared with BFT (namely psychodynamic or cognitive-behavioural psychotherapy) in Germany. Secondary, MBT's efficacy will be investigated with regard to cost-effectiveness, general and interpersonal functioning, BPD and general symptom severity, social adjustment, quality of life, reduction in psychotropic medication and therapy retention. Additionally, moderator as well as common and treatment specific mediator variables will be investigated.

Study Design/ Study Population/ Methods: Across 5 study sites in Germany, 304 individuals of all genders from age 18 to 65 with a BPD diagnosis and NSSI or suicide attempts in the past will be asked to participate in the study for two years. In the first year, patients will receive either MBT or BFT (psychodynamic or cognitive behavioural psychotherapy) and will take part in continuous scientific assessments. Scientific assessments will continue after therapy completion up to a 12-moth follow up. As primary outcome, crisis events will be assessed via ecological momentary assessment (EMA) four times a week once per month during the first year and once every three months in the second year. Number of crisis events up to 2 years post randomization will be compared between treatment arms using a log-linear regression model following an intention-to-treat approach. Secondary outcomes, such as borderline and general symptom severity, will be assessed at several timepoints. A within-trial cost-effectiveness analysis (CEA) will be conducted with a societal perspective.

Clinical Trial Rationale: This study investigates efficacy of MBT as BPD specific treatment in an outpatient setting compared with BFT in Germany. Results of this study can address a treatment gap in the German healthcare system, and inform about health economic aspects of BPD treatment as well as mechanisms of psychotherapeutic change.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Psychologische Hochschule Berlin, Berlin, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Borderline Personality Disorder
  • non-suicidal self injury or suicide attempts in the past two years as indicated by the IPDE item "repeated suicidal behaviours, gestures, threats or self-harm", one of which has occurred in the past six months

Exclusion criteria

  • acute substance use disorder (exception: cannabis dependency)
  • diagnosis of schizophrenia or schizotypal personality disorder
  • bipolar I disorder (DSM-5)
  • cognitive impairment (IQ<80) or evidence of organic brain disorder
  • BMI<16.5
  • serious medical condition that will require hospitalization within the next year (e.g. cancer)
  • no sufficient German language abilities

Treatment and study plan

Mentalization-Based Treatment (MBT)

Behavioral

Patients in MBT will receive a maximum of 58 sessions in total. Of those, 30 are weekly individual sessions. 28 sessions are weekly group sessions conducted by two therapists, and consisting of 8 introductory sessions of group psychoeducation followed by 20 group therapy sessions. The duration of MBT is 12 months. MBT is manualized and relies on validating the emotional experience of patients that aims to promote mentalizing. The proposed mechanism of change in MBT is to stabilize mentalizing in certain focus areas in order to create a psychic buffer between affect and behaviour to foster affect regulation, reduce impulsivity and promote functional supportive relationships.

Bona-Fide Treatment in Germany (BFT)

Behavioral

Patients in BFT will receive one to two weekly sessions of Bona-Fide-Treatment (Psychodynamic Therapy, PT, or Cognitive Behavioural Therapy, CBT) conducted by community experts delivered as short-term psychotherapy (<24 sessions) or long-term psychotherapy (>24 sessions). BFT can be delivered as individual, group or a combination of individual and group treatment as stated in the German psychotherapy regulations.

Primary outcomes

  1. change in crisis events assessed with Ecological Momentary Assessment with items based on the SHBQ (Gutierrez et al., 2001)

    Time frame: every second day during one week per month in the first year, and during one week every three months in the second year

    composite score (non)suicidal self injury

Secondary outcomes

  1. Symptoms of Borderline Personality Disorder assessed with the IPDE (Loranger et al., 1997) and BSL-23 (Wolf et al., 2009)

    Time frame: Day 0, Month 6, Month 12, Month 24; IPDE only at Month 24

  2. Change in psychiatric symptom severity assessed with the DASS- 21 (Lovibond & Lovibond, 1995)

    Time frame: Day 0, Month 6, Month 12, Month 24

  3. Change in health and disability assessed with WHODAS 2.0 Short Form (Üstün et al., 2010)

    Time frame: Day 0, Month 6, Month 12, Month 24

  4. Change in personality funcitioning assessed with LPFS-BF (Hutsebaut et al., 2016)

    Time frame: Day 0, Month 6, Month 12, Month 24

  5. Change in personality traits assessed with PID5BF+M (Bach et al., 2020)

    Time frame: Day 0, Month 6, Month 12, Month 24

  6. Change in threat hypersensitivity assessed with emotion classification task (Honecker et al., 2021)

    Time frame: Day 0, Month 6, Month 12, Month 24

    Participants are presented with 160 faces, each unambiguously showing one of four emotional expressions (angry, fearful, happy, neutral). The goal of the task is to correctly classify these facial expressions. The task's collected behavioral data encompasses two key measurements: the ratio of accurate responses (specifically, correct emotion classification) and the time it takes to respond in trials where the emotion classification is correct.

  7. Change in quality of life assessed with EQ-5D-5L (Herdman et al., 2011; EuroQol Research Foundation, 2019)

    Time frame: Day 0, Month 6, Month 12, Month 24

  8. Change in trait anger assessed with STAXI-2 (Spielberger, 1999)

    Time frame: Day 0, Month 6, Month 12, Month 24

  9. Change in social adjustment assessed with WSAS (Marks, 1986)

    Time frame: Day 0, Month 6, Month 12, Month 24

  10. Change in emotional reactions to social exclusion, rejection and relational devaluation with SPQ (Stangier et al., 2021)

    Time frame: Day 0, Month 6, Month 12, Month 24

  11. Change in Interoceptive Body Awareness with MAIA-2 (Mehling et al., 2018)

    Time frame: Day 0, Month 6, Month 12, Month 24

  12. Changes in medication with self-report of medication prescription via adapted version of AD-SUS (Kuyken et al., 2015)

    Time frame: Day 0, Month 6, Month 12, Month 24

  13. Heath Care utilization with an adapted version of the AD-SUS (Kuyken et al., 2015)

    Time frame: Day 0, Month 6, Month 12, Month 24

  14. Change in acute dissociative symptoms with Dissociation-Tension Scale-4 (DSS-4; Stiglmayr et al., 2003)

    Time frame: Day 0, Month 6, Month 12, Month 24

Other outcomes

  1. Mentalizing as mediator of change assessed with the Certainty About Mental States Questionnaire (CAMSQ; Müller et al., 2021)

    Time frame: Month 6, Month 12

    Mediator

  2. Therapeutic Agency Inventory (TAI; Huber et al., 2019)

    Time frame: once a week in the first year and at Month 6 and Month 12

    Mediator

  3. Group Questionnaire - short (GQ; Jensen, 2016)

    Time frame: once a week in the first year and at Month 6 and Month 12

    Mediator

  4. Epistemic Trust, Mistrust and Credulity Questionnaire (ETMCQ; Campbell et al., 2019)

    Time frame: Month 6, Month 12

    Mediator

  5. Experiences in Close Relationships-Revised Screening Version (ECR-RD8; Ehrenthal et al., 2021)

    Time frame: Month 6, Month 12

    Mediator

  6. Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004)

    Time frame: Month 6, Month 12

    Mediator

  7. Mentalizing as mediator of change assessed with Mentalizing Emotions Questionnaire (Kasper et al., submitted)

    Time frame: Month 6, Month 12

    Mediator

  8. Negative Effects Questionnaire (NEQ; Rozental et al., 2016)

    Time frame: Month 12

    Serious adverse events of therapy

  9. Therapeutic Alliance as mediator of change assessed with Working Alliance Inventory (WAI-SR, Hatcher & Gillaspy, 2006)

    Time frame: once a week in the first year and at Month 6 and Month 12

    Mediator

  10. Symptoms of PTSD and complex PTSD and complex PTSD Trauma experiences with Internation Trauma Interview (ITI; Roberts et al., 2019)

    Time frame: Day 0

    Moderator

  11. Symptoms of PTSD and complex PTSD with International Trauma Questionnaire (ITQ; Cloitre et al., 2018)

    Time frame: Day 0

    Moderator

  12. Level of personality functioning with Semi-Structured Interview for Personality Functioning DSM-5 (STiP; Hutsebaut et al., 2017)

    Time frame: Day 0

    Moderator

  13. Change of pleasure, arousal and dominance with Self-Assessment Manikin (Bradley, 1994)

    Time frame: once a week in the first year and at Month 6 and Month 12

    Mediator

  14. Change of frequency of occurence of positive and negative automatic thoughts with Automatic Thoughts Questionnaire - Revised (ATQ-R; Kendall, 1989)

    Time frame: Month 6, Month 12

    Mediator

  15. Assessment of the frequency of alliance ruptures and resolution processes in therapy sessions with Rupture Resolution Rating System (Eubanks et al., 2015)

    Time frame: Month 6, Month 12

    Mediator

  16. Assessment of the clients'attachment style with the Patient Attachment Coding System (Talia & Miller-Bottome, 2012)

    Time frame: Month 6, Month 12

    Mediator

  17. Assessment of the therapists' attunement and attachment status with the Therapist Attunement Scales (Talia & Muzi, 2017)

    Time frame: Month 6, Month 12

    Mediator

  18. Assessment of the therapists' activity and appropriateness in essential domains of MBT with the Mentalization-Based Treatment Adherence and Competence Scale (Bateman & Fonagy, 2016)

    Time frame: Month 6, Month 12

    Mediator

  19. Assessment of the therapists' adherence to psychodynamic-interpersonal and cognitive-behavioural treatments with the Comparative Psychotherapy Process Scale (Hilsenroth et al., 2005)

    Time frame: Month 6, Month 12

    Mediator

  20. Interview for treatment and study evaluation

    Time frame: Month 24

    Semi-structured interview developed based on Krause et al. 2016 will be used to assess how patients experienced the therapy and the study, what aspects they perceived as positive or negative, and what impact the therapy had on their symptoms and their life

Study contacts

Contact information is provided by the study sponsor or research team.

Sophie Hauschild, Dr.

CONTACT

[email protected]

Svenja Taubner, Prof.

CONTACT

[email protected]

+496221564701

Sponsors and collaborators

Lead sponsor

Heidelberg University

Other

Collaborators

  • German Research Foundation
  • Jena University Hospital
  • Psychologische Hochschule Berlin
  • University Düsseldorf
  • Universitätsklinikum Ulm

Registry information

Official study title

Mentalisierungsbasierte Therapie Versus Bona-fide-Therapie für Patient:Innen Mit Borderline-Persönlichkeitsstörung in Deutschland (MaGnet): Eine Prospektive, Multizentrische Randomisiert-kontrollierte Studie Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany (MAGNET): a Prospective, Multi-centre Randomized Controlled Trial

Acronym: MAGNET

Important dates

Study start
2024
Primary completion
2027
Study completion
2028
First posted
Aug 30, 2023
Registry last updated
May 10, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.